Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

Supporting evidence

• Review decision

• Review Decision (TA241) – January 2016

• Appendix A (TA241) - RPP decision paper - January 2016 (PDF 143 KB)

  Published:

  26 January 2016